Compare Stocks

Date Range: 

 Canopy GrowthBausch Health CompaniesMERCK Kommanditgesellschaft auf AktienAphriaHikma Pharmaceuticals
SymbolTSE:WEEDTSE:BHCETR:MRKTSE:APHALON:HIK
Price Information
Current PriceC$30.68C$34.08€142.75C$16.55GBX 2,350
52 Week RangeHoldBuyN/AHoldBuy
MarketRank™
Overall Score1.31.50.91.11.6
Analysis Score3.83.50.03.12.5
Community Score2.62.82.92.62.8
Dividend Score0.00.00.80.01.7
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.01.30.60.01.3
Analyst Ratings
Consensus RecommendationHoldBuyN/AHoldBuy
Consensus Price TargetC$38.46C$47.75N/AC$18.34GBX 2,753.33
% Upside from Price Target25.37% upside40.11% upsideN/A10.81% upside17.16% upside
Trade Information
Market CapC$11.73 billionC$12.21 billion$18.45 billionC$5.24 billion£5.42 billion
BetaN/AN/AN/AN/AN/A
Average Volume1,524,042668,580N/A6,075,528424,692
Sales & Book Value
Annual RevenueC$506.12 millionC$8.04 billion$17.53 billionC$611.06 million£2.34 billion
Price / Sales23.181.521.058.582.32
CashflowC$4.28 per shareC$1.89 per share€3.23 per shareC$0.74 per shareGBX 145.04 per share
Price / Cash7.1717.9844.1422.4016.20
Book ValueC$10.59 per shareC($0.55) per share€38.98 per shareC$4.76 per shareGBX 926.40 per share
Price / Book2.90-61.963.663.480.03
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC($6.43)C($3.48)€4.57C($2.01)GBX 131.10
Trailing P/E RatioN/AN/A31.24N/A17.93
Forward P/E Ratio
P/E GrowthN/A0.56N/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/A€1.40N/AGBX 0.46
Dividend YieldN/AN/A0.98%N/A0.02%
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/A30.63%N/A0.35%
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio17.92%4,000.66%71.35%59.29%43.39%
Current Ratio6.24%1.10%1.01%3.37%1.87%
Quick Ratio4.90%0.45%0.61%1.63%1.05%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees2,70021,60058,1271,2008,600
Shares Outstanding382.32 million358.40 million129.24 million316.80 million230.77 million
Next Earnings Date6/1/2021 (Estimated)8/5/2021 (Estimated)5/12/2021 (Estimated)7/27/2021 (Estimated)N/A
OptionableNot OptionableOptionableOptionableOptionableNot Optionable
SourceHeadline
Barclays Reiterates Overweight Rating for Hikma Pharmaceuticals (LON:HIK)Barclays Reiterates Overweight Rating for Hikma Pharmaceuticals (LON:HIK)
americanbankingnews.com - May 7 at 9:54 AM
Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200-Day Moving Average of $2,450.87Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200-Day Moving Average of $2,450.87
americanbankingnews.com - May 5 at 2:18 AM
(COVID-19 Updates) Saudi Arabia Pharmaceutical Drugs Market is Generating Revenue of US$ 16,663.1 Million by 2027, At a CAGR 7.3% | CMI(COVID-19 Updates) Saudi Arabia Pharmaceutical Drugs Market is Generating Revenue of US$ 16,663.1 Million by 2027, At a CAGR 7.3% | CMI
pharmiweb.com - May 4 at 7:52 AM
US approves Hikma’s high-dose opioid reversal nasal sprayUS approves Hikma’s high-dose opioid reversal nasal spray
cbs4indy.com - May 2 at 6:33 PM
Hikma Pharma gets USFDA nod for Kloxxado nasal sprayHikma Pharma gets USFDA nod for Kloxxado nasal spray
medicaldialogues.in - May 2 at 3:32 AM
Hikma predicts generics revenue at top of guidanceHikma predicts generics revenue at top of guidance
hl.co.uk - April 30 at 10:47 AM
Hikma Pharmaceutical - Hikma announces US FDA approval of KLOXXADOHikma Pharmaceutical - Hikma announces US FDA approval of KLOXXADO
proactiveinvestors.co.uk - April 30 at 10:47 AM
Hikma announces good start to 2021 and reiterates full year guidanceHikma announces good start to 2021 and reiterates full year guidance
pharmiweb.com - April 30 at 10:47 AM
Hikma makes strong start to year, receives approval for opioid treatmentHikma makes strong start to year, receives approval for opioid treatment
msn.com - April 30 at 10:47 AM
Hikma Pharma Issues Trading Update; Announces FDA Approval Of KLOXXADOHikma Pharma Issues Trading Update; Announces FDA Approval Of KLOXXADO
nasdaq.com - April 30 at 10:47 AM
Celgene Sues Hikma To Block Revlimid GenericCelgene Sues Hikma To Block Revlimid Generic
law360.com - April 29 at 6:46 PM
Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa RegionMelinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region
finance.yahoo.com - April 29 at 8:45 AM
Hyloris Pharmaceuticals SA: Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic IVHyloris Pharmaceuticals SA: Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic IV
finanznachrichten.de - April 28 at 4:34 AM
Why the AFT Pharmaceuticals (ASX:AFP) share price is in focusWhy the AFT Pharmaceuticals (ASX:AFP) share price is in focus
msn.com - April 27 at 10:33 PM
Auckland pharma company signs deal with US distributorAuckland pharma company signs deal with US distributor
rnz.co.nz - April 27 at 10:33 PM
Drug companys shares surge after deal signed in worlds largest marketDrug company's shares surge after deal signed in world's largest market
stuff.co.nz - April 27 at 10:33 PM
Novacyt or AstraZeneca: which biotech stock should I buy?Novacyt or AstraZeneca: which biotech stock should I buy?
fool.co.uk - April 27 at 12:32 PM
Glenmark Pharma secures European approval for Ryaltris nasal spray to treat allergic rhinitisGlenmark Pharma secures European approval for Ryaltris nasal spray to treat allergic rhinitis
medicaldialogues.in - April 27 at 7:31 AM
Glenmarks Ryaltrisreg; nasal spray now approved in EuropeGlenmark's Ryaltrisreg; nasal spray now approved in Europe
bignewsnetwork.com - April 26 at 12:44 PM
Will soon launch nasal spray Ryaltris in EU, says GlenmarkWill soon launch nasal spray Ryaltris in EU, says Glenmark
sify.com - April 26 at 12:44 PM
Glenmarks Ryaltris nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of ageGlenmark's Ryaltris nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age
news.webindia123.com - April 26 at 7:43 AM
Glenmark Pharma to launch its nasal spray Ryaltris in European UnionGlenmark Pharma to launch its nasal spray Ryaltris in European Union
moneycontrol.com - April 26 at 7:43 AM
Glenmarks Ryaltris nasal spray now approved in Europe for theGlenmark's Ryaltris nasal spray now approved in Europe for the
business-standard.com - April 26 at 7:43 AM
Global Breast Cancer Treatment Market Size Will Reach to USD 34.06 Billion by 2026: Facts & FactorsGlobal Breast Cancer Treatment Market Size Will Reach to USD 34.06 Billion by 2026: Facts & Factors
marketwatch.com - April 22 at 1:16 PM
Hikma’s US breakthrough for inhalerHikma’s US breakthrough for inhaler
thetimes.co.uk - April 21 at 9:48 PM
DateCompanyBrokerageAction
4/9/2021Canopy GrowthCowenLower Price Target
2/24/2021Canopy GrowthEight CapitalDowngrade
2/24/2021Canopy GrowthJefferies Financial GroupBoost Price Target
2/10/2021Canopy GrowthAlliance Global PartnersBoost Price Target
2/10/2021Canopy GrowthBenchmarkDowngrade
2/10/2021Canopy GrowthCIBCBoost Price Target
2/10/2021Canopy GrowthCormarkDowngrade
2/10/2021Canopy GrowthMKM PartnersBoost Price Target
2/10/2021Canopy GrowthStifel NicolausBoost Price Target
2/10/2021Canopy GrowthCanaccord GenuityBoost Price Target
6/1/2020Canopy GrowthPi FinancialDowngrade
4/30/2021Bausch Health CompaniesRoyal Bank of CanadaReiterated Rating
2/25/2021Bausch Health CompaniesBarclaysBoost Price Target
2/21/2019Bausch Health CompaniesBMO Capital MarketsLower Price Target
8/8/2018Bausch Health CompaniesCantor FitzgeraldReiterated Rating
4/13/2021AphriaHaywood SecuritiesLower Price Target
4/13/2021AphriaStandpoint ResearchLower Price Target
2/1/2021Hikma PharmaceuticalsCitigroupReiterated Rating
9/2/2020Hikma PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated Rating
7/30/2020Hikma PharmaceuticalsPeel HuntBoost Price Target
7/7/2020Hikma PharmaceuticalsMorgan StanleyUpgrade
4/24/2020Hikma PharmaceuticalsThe Goldman Sachs GroupDowngrade
4/2/2020Hikma PharmaceuticalsJPMorgan Chase & Co.Upgrade
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.